Palazestrant in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile.
SAN FRANCISCO, Dec. 04, 2023 Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for.
Olema Pharmaceuticals Stock: Advancing On Multiple Fronts (NASDAQ:OLMA) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with.